Thursday, October 1, 2026

°

Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch

Posted Monday, September 28, 2026 4:32 pm

Frank Vinluan (via MedCity News)

Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. This class of targeted cancer therapies includes clinical-stage assets from Revolution Medicines, BridgeBio Oncology Therapeutics, and Verastem Oncology. The post Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch appeared first on MedCity News.

Continue reading at MedCity News »

Keywords

BioPharma, Pharma, biopharma nl, cancer, China, Clinical Trials, Deals, KRAS, Merck, oncology, SciBrunch Therapeutics, Startups

Top stories

Ask About Clinical Trials on Day One

(Mitch Jelniker) - For people diagnosed with small cell lung cancer, the clinical trial conversation belongs in the very first appointment.A diagnosis of SCLC can trigger a whirlwind of appointments, …

From Uncertainty to Reassurance: How a Small Heart Monitor and Ablation Procedure Helped One Father Conquer the Unknowns of Atrial Fibrillation

(NewsUSA) - In 2018, then-52-year-old Todd Repass Jr. stood up after a meal and immediately knew something was wrong. It was terrifying. He felt weak, short of breath, and, at times, dizzy. The …

Youth Tobacco Use Is at Historic Lows. Adult Smokers Still Need Better Choices.

(Dr. Matthew Holman) - There is a piece of good public health news that deserves more attention: youth tobacco use in the United States has fallen to historically low levels. That progress did not …

America’s New Drug Dealers Have Moved from Street Corners to the Internet – and the FDA is Letting Them

(Peter Pitts, President and Co-founder of the Center for Medicine in the Public Interest ) - Consumers purchasing retatrutide online may think they are buying a safe, clinically tested weight-loss …

Hear from a prostate cancer patient about the one test more men should ask for

(Novartis) - Dr. Koo, EVP and CMO at Prostate Cancer Foundation, and Bill, who is living with prostate cancer, answer some frequently asked questions about PSMA testing. Talk to your doctor and visit …

From the web

Sanofi Puts Up $1B to Expand Regeneron Alliance and Develop Next-Gen Dupixent

Sanofi and Regeneron Pharmaceuticals will collaborate on four next-generation antibody drugs that could offer advantages over Dupixent, the blockbuster immunology drug spawned by their R&D alliance. …

InvestorNewsBreaks – Beeline Holdings Inc. (NASDAQ: BLNE) Showcases Digital Mortgage Platform and New Paths to Homeownership

Beeline Holdings (NASDAQ: BLNE), a technology-driven mortgage lender and fractional equity platform, recently partnered with Emmy Award-winning Loft 100 Studios to produce a 45-minute …

'It's a nightmare.' Former refugee, professor on Trump's new Medicaid policy

Starting Oct. 1, many immigrants who are here legally lose their Medicaid coverage because of the Republican budget bill passed last year.

A new California law bans child marriage. What's the global outlook on the practice?

The governor of California has signed into law a ban on child marriage. What is the status of other efforts to ban the practice? And do bans prove effective?

AINewsBreaks – AZIO AI Holdings Inc. (NASDAQ: AZIO) Targets Infrastructure Bottleneck with Power-First Strategy

AZIO AI Holdings (NASDAQ: AZIO) was featured in a recent article that discussed its positioning as an integrated AI compute infrastructure company focused on addressing a growing constraint on AI …